Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Request for Proposals: Generic Drug Repurposing

Coefficient Giving

Promising treatments for some of the world’s most neglected but high-burden diseases may already exist — sitting on pharmacy shelves around the world, manufactured at scale, and costing a fraction of new medicines. They just haven’t been tested for the right indication yet.

Generic drug repurposing offers a powerful and speedy route to new treatments. These medicines typically have well-characterized safety profiles, are already registered with regulatory authorities, and already flow through local supply chains. They’re usually affordable, because they are long off-patent and produced by multiple manufacturers. The path to patient impact can be dramatically shorter and cheaper than for a novel compound: the drug is made, the toxicology is done, and the regulatory pathway is partially cleared.

Yet precisely because these medicines cannot be patent-protected, the commercial incentive to test them for new uses is absent. We believe there may be several plausible high-impact opportunities — supported by mechanistic evidence, pharmacokinetic data, and early clinical signals — that remain untested simply because no one will pay to investigate them.

Coefficient Giving is launching this Request for Proposals to fund rigorous investigations of repurposed generic drugs for high-burden[1] yet neglected diseases. We are seeking proposals to move promising candidates toward clinical evidence of efficacy — leveraging the speed, cost, and access advantages that repurposing offers to deliver new treatment options for patients who cannot wait for the next generation of drug discovery.

The aim of this RFP is to provide grants for clinical repurposing trials aimed at benefitting patients from low- and lower-middle-income countries (LMICs) as defined by the World Bank.

Deadline for LOI: May 11, 2026

Specialties

International Opportunities

Medical - Clinical Science

Medical

Medical - Translational

Eligibility Requirements

Repurposed therapies must be approved/recognized as safe for human use by a WHO-Listed Authority, e.g. the U.S. FDA or European Medicines Agency.
Generic drugs, nutraceuticals, supplements, indigenous medicine, combination therapies, and vaccines are eligible.
May include host-directed therapies.
Applicants may be based anywhere in the world.
Therapies must be repurposed, i.e. tested in a new indication for which they are not already approved/widely used in clinical practice.
- This may include population expansion — e.g. demonstrating a generic medicine is safe and effective to use in pregnant women or children.
- This may include combination therapies in which one or more components are a generic repurposed medicine.
Eligible institutions must have a research Institutional Review Board, Ethics Review Committee, or similar in place.
Applicants must have past or current experience with human clinical research.
Proposed plans must follow the WHO’s or other regulatory agencies’ standards for Good Laboratory Practice (GLP), Good Clinical Practice (GCP), and Good Laboratory and Clinical Practice (GLCP).

Sponsor Details

Sponsor Institute/Organizations: Coefficient Giving

Sponsor Type:

Address: NA

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity